Literature DB >> 19834889

Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors.

Marina Naldi1, Natalia Calonghi, Lanfranco Masotti, Carola Parolin, Sergio Valente, Antonello Mai, Vincenza Andrisano.   

Abstract

The goal of the present work is to establish a correlation between the degree of histone post-translational modifications and the effects caused by treatment of HT29 colon cancer cells with class I-selective (MS-275 and MC1855), class II-selective (MC1568), and non-selective (suberoylanilide hydroxamic acid (SAHA) histone deacetylase inhibitors (HDACi). This correlation could afford a mean to better understand the mechanism of action of new, more potent, and selective HDACi directly on the cells. To this end, LC coupled to MS was applied in studies of time and concentration-dependent treatment with HDACi in HT29 cells. The results were correlated to their potency of histone deacetylase inhibition and to their effects on the cell cycle. The results indicate that the four tested inhibitors show a different pattern of time- and concentration-dependent modification after treatment of HT29 cells. At the selected concentrations, they cause different histone hyperacetylation and different cell cycle effects. In particular, SAHA (non-selective HDACi) affected hyperacetylation of all histones and caused massive cell death. MC1855 (class I-selective HDACi, hydroxamate) proved to be more potent and less toxic (cell arrest in G2/M phase) than SAHA. MS-275 (class I-selective HDACi, benzamide) exhibited a higher degree of hyperacetylation of H4 and a lower degree of H2A, H2B, and H3 acetylation, causing a cell arrest in G0/G1 phase. On the contrary, MC1568 (class II-selective HDACi) produced only a modest hyperacetylation of H4, was ineffective on the other histones, and showed no effect on cell cycle in HT29 cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834889     DOI: 10.1002/pmic.200800866

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  9 in total

1.  Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.

Authors:  Hazem Abdelkarim; Raghupathi Neelarapu; Antonett Madriaga; Aditya S Vaidya; Irida Kastrati; Bhargava Karumudi; Yue-Ting Wang; Taha Y Taha; Gregory R J Thatcher; Jonna Frasor; Pavel A Petukhov
Journal:  ChemMedChem       Date:  2017-11-30       Impact factor: 3.466

Review 2.  Largazole: from discovery to broad-spectrum therapy.

Authors:  Jiyong Hong; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2012-02-14       Impact factor: 13.423

3.  Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.

Authors:  Luisa Quinti; Vanita Chopra; Dante Rotili; Sergio Valente; Allison Amore; Gianluigi Franci; Sarah Meade; Marta Valenza; Lucia Altucci; Michele M Maxwell; Elena Cattaneo; Steven Hersch; Antonello Mai; Aleksey Kazantsev
Journal:  PLoS Curr       Date:  2010-09-02

4.  Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers.

Authors:  F F Wagner; Y-L Zhang; D M Fass; N Joseph; J P Gale; M Weïwer; P McCarren; S L Fisher; T Kaya; W-N Zhao; S A Reis; K M Hennig; M Thomas; B C Lemercier; M C Lewis; J S Guan; M P Moyer; E Scolnick; S J Haggarty; L-H Tsai; E B Holson
Journal:  Chem Sci       Date:  2015-01-01       Impact factor: 9.825

5.  Site-specific quantification of lysine acetylation in the N-terminal tail of histone H4 using a double-labelling, targeted UHPLC MS/MS approach.

Authors:  Annalisa D'Urzo; Alexander P Boichenko; Thea van den Bosch; Jos Hermans; Frank Dekker; Vincenza Andrisano; Rainer Bischoff
Journal:  Anal Bioanal Chem       Date:  2016-03-11       Impact factor: 4.142

6.  Hypoxia and hypoxia mimetics differentially modulate histone post-translational modifications.

Authors:  Kuo-Feng Hsu; Sarah E Wilkins; Richard J Hopkinson; Rok Sekirnik; Emily Flashman; Akane Kawamura; James S O McCullagh; Louise J Walport; Christopher J Schofield
Journal:  Epigenetics       Date:  2020-07-01       Impact factor: 4.528

7.  Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29.

Authors:  Inge Mannaerts; Nathalie Eysackers; Oscar O Onyema; Katrien Van Beneden; Sergio Valente; Antonello Mai; Margarete Odenthal; Leo A van Grunsven
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

8.  Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer.

Authors:  S Ishikawa; H Hayashi; K Kinoshita; M Abe; H Kuroki; R Tokunaga; S Tomiyasu; H Tanaka; H Sugita; T Arita; Y Yagi; M Watanabe; M Hirota; H Baba
Journal:  Int J Cancer       Date:  2014-01-06       Impact factor: 7.396

9.  Indole Derivative Interacts with Estrogen Receptor Beta and Inhibits Human Ovarian Cancer Cell Growth.

Authors:  Laura Verardi; Jessica Fiori; Vincenza Andrisano; Alessandra Locatelli; Rita Morigi; Marina Naldi; Carlo Bertucci; Elena Strocchi; Carla Boga; Gabriele Micheletti; Natalia Calonghi
Journal:  Molecules       Date:  2020-09-27       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.